Literature DB >> 2942099

In vitro evaluation of A-56619 and A-56620, two new quinolones.

A L Barry, C Thornsberry, R N Jones.   

Abstract

The in vitro activities of two new aryl-fluoroquinolones (A-56619 and A-56620) were compared with those of ciprofloxacin, ofloxacin, enoxacin, and norfloxacin. All six quinolones had broad spectra of antibacterial activity; the streptococci, Pseudomonas maltophilia, and Pseudomonas cepacia were the least susceptible. A-56619, A-56620, and chloramphenicol had similar activity against anaerobic bacteria. With both drugs, a low frequency of resistant variants (less than 10(-8)) was observed. By regression analysis, A-56619 MICs correlated best with ofloxacin MICs and A-56620 was most similar to ciprofloxacin.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2942099      PMCID： PMC180360          DOI： 10.1128/AAC.29.1.40

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  4 in total

1.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

2.  In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains.

Authors:  C N Baker; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

3.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

4.  In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191
  4 in total
  10 in total

1.  In vitro activity of the two new 4-quinolones A56619 and A56620 against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum and Gardnerella vaginalis.

Authors:  K H Tjiam; J H Wagenvoort; B van Klingeren; P Piot; E Stolz; M F Michel
Journal:  Eur J Clin Microbiol       Date:  1986-10       Impact factor: 3.267

2.  In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

Authors:  N Khardori; A Reuben; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

3.  In vitro activity of A-56619 (difloxacin), A-56620, and other new quinolone antimicrobial agents against genital pathogens.

Authors:  L D Liebowitz; J Saunders; G Fehler; R C Ballard; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

4.  Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer.

Authors:  K V Rolston; M Messer; D H Ho
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

5.  Difloxacin metabolism and pharmacokinetics in humans after single oral doses.

Authors:  G R Granneman; K M Snyder; V S Shu
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

Review 6.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

7.  In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy.

Authors:  D F Sahm; G T Koburov
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

8.  In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents.

Authors:  N Khardori; H Nguyen; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

9.  Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620.

Authors:  L Hirschhorn; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

10.  High-pressure liquid chromatography and microbiological assay of serum ofloxacin levels in adults receiving intravenous and oral therapy for skin infections.

Authors:  G M Auten; L C Preheim; M Sookpranee; M J Bittner; T Sookpranee; A Vibhagool
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.